The multiple de novo copy number variant (MdnCNV) phenomenon presents with peri-zygotic DNA mutational signatures and multilocus pathogenic variation.

De novo CNV De novo SNV, Human Phenotype Ontology, Structural variation Genomic data integration, Genomic data visualization, MMBIR Genomic instability Long-read sequencing Tandem duplication

Journal

Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844

Informations de publication

Date de publication:
27 10 2022
Historique:
received: 04 03 2022
accepted: 10 10 2022
entrez: 28 10 2022
pubmed: 29 10 2022
medline: 1 11 2022
Statut: epublish

Résumé

The multiple de novo copy number variant (MdnCNV) phenotype is described by having four or more constitutional de novo CNVs (dnCNVs) arising independently throughout the human genome within one generation. It is a rare peri-zygotic mutational event, previously reported to be seen once in every 12,000 individuals referred for genome-wide chromosomal microarray analysis due to congenital abnormalities. These rare families provide a unique opportunity to understand the genetic factors of peri-zygotic genome instability and the impact of dnCNV on human diseases. Chromosomal microarray analysis (CMA), array-based comparative genomic hybridization, short- and long-read genome sequencing (GS) were performed on the newly identified MdnCNV family to identify de novo mutations including dnCNVs, de novo single-nucleotide variants (dnSNVs), and indels. Short-read GS was performed on four previously published MdnCNV families for dnSNV analysis. Trio-based rare variant analysis was performed on the newly identified individual and four previously published MdnCNV families to identify potential genetic etiologies contributing to the peri-zygotic genomic instability. Lin semantic similarity scores informed quantitative human phenotype ontology analysis on three MdnCNV families to identify gene(s) driving or contributing to the clinical phenotype. In the newly identified MdnCNV case, we revealed eight de novo tandem duplications, each ~ 1 Mb, with microhomology at 6/8 breakpoint junctions. Enrichment of de novo single-nucleotide variants (SNV; 6/79) and de novo indels (1/12) was found within 4 Mb of the dnCNV genomic regions. An elevated post-zygotic SNV mutation rate was observed in MdnCNV families. Maternal rare variant analyses identified three genes in distinct families that may contribute to the MdnCNV phenomenon. Phenotype analysis suggests that gene(s) within dnCNV regions contribute to the observed proband phenotype in 3/3 cases. CNVs in two cases, a contiguous gene duplication encompassing PMP22 and RAI1 and another duplication affecting NSD1 and SMARCC2, contribute to the clinically observed phenotypic manifestations. Characteristic features of dnCNVs reported here are consistent with a microhomology-mediated break-induced replication (MMBIR)-driven mechanism during the peri-zygotic period. Maternal genetic variants in DNA repair genes potentially contribute to peri-zygotic genomic instability. Variable phenotypic features were observed across a cohort of three MdnCNV probands, and computational quantitative phenotyping revealed that two out of three had evidence for the contribution of more than one genetic locus to the proband's phenotype supporting the hypothesis of de novo multilocus pathogenic variation (MPV) in those families.

Sections du résumé

BACKGROUND
The multiple de novo copy number variant (MdnCNV) phenotype is described by having four or more constitutional de novo CNVs (dnCNVs) arising independently throughout the human genome within one generation. It is a rare peri-zygotic mutational event, previously reported to be seen once in every 12,000 individuals referred for genome-wide chromosomal microarray analysis due to congenital abnormalities. These rare families provide a unique opportunity to understand the genetic factors of peri-zygotic genome instability and the impact of dnCNV on human diseases.
METHODS
Chromosomal microarray analysis (CMA), array-based comparative genomic hybridization, short- and long-read genome sequencing (GS) were performed on the newly identified MdnCNV family to identify de novo mutations including dnCNVs, de novo single-nucleotide variants (dnSNVs), and indels. Short-read GS was performed on four previously published MdnCNV families for dnSNV analysis. Trio-based rare variant analysis was performed on the newly identified individual and four previously published MdnCNV families to identify potential genetic etiologies contributing to the peri-zygotic genomic instability. Lin semantic similarity scores informed quantitative human phenotype ontology analysis on three MdnCNV families to identify gene(s) driving or contributing to the clinical phenotype.
RESULTS
In the newly identified MdnCNV case, we revealed eight de novo tandem duplications, each ~ 1 Mb, with microhomology at 6/8 breakpoint junctions. Enrichment of de novo single-nucleotide variants (SNV; 6/79) and de novo indels (1/12) was found within 4 Mb of the dnCNV genomic regions. An elevated post-zygotic SNV mutation rate was observed in MdnCNV families. Maternal rare variant analyses identified three genes in distinct families that may contribute to the MdnCNV phenomenon. Phenotype analysis suggests that gene(s) within dnCNV regions contribute to the observed proband phenotype in 3/3 cases. CNVs in two cases, a contiguous gene duplication encompassing PMP22 and RAI1 and another duplication affecting NSD1 and SMARCC2, contribute to the clinically observed phenotypic manifestations.
CONCLUSIONS
Characteristic features of dnCNVs reported here are consistent with a microhomology-mediated break-induced replication (MMBIR)-driven mechanism during the peri-zygotic period. Maternal genetic variants in DNA repair genes potentially contribute to peri-zygotic genomic instability. Variable phenotypic features were observed across a cohort of three MdnCNV probands, and computational quantitative phenotyping revealed that two out of three had evidence for the contribution of more than one genetic locus to the proband's phenotype supporting the hypothesis of de novo multilocus pathogenic variation (MPV) in those families.

Identifiants

pubmed: 36303224
doi: 10.1186/s13073-022-01123-w
pii: 10.1186/s13073-022-01123-w
pmc: PMC9609164
doi:

Substances chimiques

DNA 9007-49-2
Nucleotides 0
SMARCC2 protein, human 0
DNA-Binding Proteins 0
Transcription Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

122

Subventions

Organisme : NHGRI NIH HHS
ID : UM1 HG008898
Pays : United States
Organisme : NHLBI NIH HHS
ID : UM1 HG006542
Pays : United States
Organisme : NHGRI NIH HHS
ID : R35 HG011311
Pays : United States
Organisme : NINDS NIH HHS
ID : R35 NS105078
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM132589
Pays : United States
Organisme : NHGRI NIH HHS
ID : R35HG011311
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM106373
Pays : United States
Organisme : NHGRI NIH HHS
ID : K08 HG008986
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG011758
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Hum Mutat. 2020 Nov;41(11):1833-1847
pubmed: 32906206
Genet Med. 2020 Feb;22(2):245-257
pubmed: 31690835
Cell Rep. 2013 Jan 31;3(1):246-59
pubmed: 23318258
Eur J Hum Genet. 2014 Jan;22(1):79-87
pubmed: 23695279
Environ Mol Mutagen. 2015 Jun;56(5):419-36
pubmed: 25892534
Bioinformatics. 2007 Mar 15;23(6):657-63
pubmed: 17234643
Am J Med Genet A. 2012 Nov;158A(11):2807-14
pubmed: 22991245
Hum Mutat. 2013 Dec;34(12):1615-8
pubmed: 24027083
Am J Hum Genet. 2009 Apr;84(4):524-33
pubmed: 19344873
Am J Hum Genet. 2015 Nov 5;97(5):691-707
pubmed: 26544804
Nat Genet. 2018 Oct;50(10):1388-1398
pubmed: 30202056
Environ Mol Mutagen. 2010 Jul;51(6):520-6
pubmed: 20658645
Hum Genet. 2021 Apr;140(4):681-690
pubmed: 33389145
Nat Methods. 2018 Jun;15(6):461-468
pubmed: 29713083
Nature. 1978 Aug 24;274(5673):775-80
pubmed: 355893
Bioinformatics. 2017 Oct 01;33(19):3088-3090
pubmed: 28575171
Nature. 2022 May;605(7910):503-508
pubmed: 35545669
PLoS Biol. 2008 Oct 7;6(10):e245
pubmed: 18842067
Cell. 2017 Feb 23;168(5):830-842.e7
pubmed: 28235197
Nature. 2014 Nov 20;515(7527):402-5
pubmed: 25409831
Nature. 2006 Dec 21;444(7122):1038-43
pubmed: 17183314
Bioinformatics. 2020 May 1;36(10):3268-3270
pubmed: 32061125
J Comput Biol. 2015 Jun;22(6):498-509
pubmed: 25658651
Mol Biol Cell. 2012 Aug;23(16):3240-53
pubmed: 22718908
N Engl J Med. 2017 Jan 5;376(1):21-31
pubmed: 27959697
Science. 2019 Jan 25;363(6425):
pubmed: 30679340
Genome Res. 2010 Nov;20(11):1469-81
pubmed: 20841430
Hum Mutat. 2022 Jul;43(7):900-918
pubmed: 35344616
Nature. 2020 May;581(7809):444-451
pubmed: 32461652
Nucleic Acids Res. 2013 Jan;41(Database issue):D94-D100
pubmed: 23125372
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Cell. 2019 Mar 7;176(6):1310-1324.e10
pubmed: 30827684
Am J Hum Genet. 2021 Feb 4;108(2):269-283
pubmed: 33545030
Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4141-4146
pubmed: 28373564
Bioinformatics. 2017 Apr 1;33(7):1104-1106
pubmed: 28062448
Nat Genet. 2016 Feb;48(2):126-133
pubmed: 26656846
J Mol Biol. 2013 Jun 12;425(11):1881-1898
pubmed: 23458407
Nature. 2017 Mar 30;543(7647):714-718
pubmed: 28329761
Nucleic Acids Res. 2019 Jan 8;47(D1):D1018-D1027
pubmed: 30476213
Genet Med. 2005 Jul-Aug;7(6):422-32
pubmed: 16024975
Am J Hum Genet. 2021 Mar 4;108(3):502-516
pubmed: 33596411
Protein Sci. 2020 Jan;29(1):111-119
pubmed: 31606900
HGG Adv. 2021 Dec 03;3(1):100074
pubmed: 35047859
Nature. 2012 Aug 23;488(7412):471-5
pubmed: 22914163
Cancer Res. 2009 Feb 1;69(3):1071-9
pubmed: 19141647
Nucleic Acids Res. 2021 Jan 8;49(D1):D1207-D1217
pubmed: 33264411
Am J Hum Genet. 2021 Apr 1;108(4):597-607
pubmed: 33675682
Genome Med. 2018 Apr 25;10(1):33
pubmed: 29695279
Genome Med. 2017 Mar 21;9(1):26
pubmed: 28327206
Trends Genet. 2008 Feb;24(2):70-6
pubmed: 18192062
Nature. 2017 Nov 30;551(7682):590-595
pubmed: 29168504
Am J Med Genet A. 2022 Mar;188(3):735-750
pubmed: 34816580
Annu Rev Biochem. 2005;74:283-315
pubmed: 15952889
Nucleic Acids Res. 2019 Jul 2;47(W1):W566-W570
pubmed: 31106327
Nat Genet. 2013 Nov;45(11):1319-26
pubmed: 24056715
Hum Mol Genet. 2009 Jun 15;18(12):2188-203
pubmed: 19324899
PLoS Biol. 2010 Nov 23;8(11):e1000543
pubmed: 21124890
Nat Genet. 2014 Oct;46(10):1063-71
pubmed: 25217958

Auteurs

Haowei Du (H)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.

Angad Jolly (A)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Medical Scientist Training Program, Baylor College of Medicine, Houston, TX, 77030, USA.

Christopher M Grochowski (CM)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.

Bo Yuan (B)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Baylor Genetics Laboratory, Houston, TX, 77021, USA.
Seattle Children's Hospital, Seattle, WA, 98105, USA.
Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030, USA.

Moez Dawood (M)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Medical Scientist Training Program, Baylor College of Medicine, Houston, TX, 77030, USA.
Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030, USA.

Shalini N Jhangiani (SN)

Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030, USA.

He Li (H)

Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030, USA.

Donna Muzny (D)

Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030, USA.

Jawid M Fatih (JM)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.

Zeynep Coban-Akdemir (Z)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.

Mary Esther Carlin (ME)

Division of Genetics and Metabolism, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Angela E Scheuerle (AE)

Division of Genetics and Metabolism, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Division of Genetics Diagnostics, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Karin Witzl (K)

Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, 1000, Ljubljana, Slovenia.
Medical Faculty, University of Ljubljana, 1000, Ljubljana, Slovenia.

Jennifer E Posey (JE)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.

Matthew Pendleton (M)

Oxford Nanopore Technologies Inc, New York, NY, 10013, USA.

Eoghan Harrington (E)

Oxford Nanopore Technologies Inc, New York, NY, 10013, USA.

Sissel Juul (S)

Oxford Nanopore Technologies Inc, New York, NY, 10013, USA.

P J Hastings (PJ)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Dan L. Duncan Comprehensive Cancer Center, BCM, Houston, TX, 77030, USA.

Weimin Bi (W)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Baylor Genetics Laboratory, Houston, TX, 77021, USA.

Richard A Gibbs (RA)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030, USA.

Fritz J Sedlazeck (FJ)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030, USA.

James R Lupski (JR)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. jlupski@bcm.edu.
Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030, USA. jlupski@bcm.edu.
Department of Pediatrics, Baylor College of Medicine, Houston, TX, 77030, USA. jlupski@bcm.edu.
Texas Children's Hospital, Houston, TX, 77030, USA. jlupski@bcm.edu.

Claudia M B Carvalho (CMB)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. ccarvalho@pnri.org.
Pacific Northwest Research Institute, 720 Broadway, Seattle, WA, 98122, USA. ccarvalho@pnri.org.

Pengfei Liu (P)

Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. pengfeil@bcm.edu.
Baylor Genetics Laboratory, Houston, TX, 77021, USA. pengfeil@bcm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH